Video

David Brandes, MD

Publish date: January 30, 2014

At the Southern Clinical Neurological Society's 41st Annual Meeting, David W. Brandes, MD, Discussed the Future of Alemtuzumab

 

Online-Only Materials

AttachmentSize
File Brandes.mp4.mp437.02 MB

Recommended Reading

Repetitive TMS May Reduce Depression and Fatigue in Patients With MS
MDedge Neurology
Risk Stratification May Mitigate Adverse Events Associated With Newer MS Drugs
MDedge Neurology
Remyelination May Continue Despite Age in Patients With MS
MDedge Neurology
New and Noteworthy Information—January 2014
MDedge Neurology
How Early Should MS Treatment Begin?
MDedge Neurology
How Do Smoking and Epstein–Barr Virus Affect Risk of MS?
MDedge Neurology
Glutamate Level Decreases Significantly in Patients With Secondary Progressive MS
MDedge Neurology
IV Immunoglobulin Increases JCV Antibody Levels in Patients With MS
MDedge Neurology
Online stem cell clinics lack adequate regulation, researchers charge
MDedge Neurology
FDA wants more data before approving alemtuzumab for MS
MDedge Neurology